NEO-PV 01

Drug Profile

NEO-PV 01

Alternative Names: NEO-PV-01; Neoantigen-based vaccine - Neon Therapeutics; NeoVax

Latest Information Update: 11 Nov 2016

Price : $50

At a glance

  • Originator Broad Institute; Dana-Farber Cancer Institute
  • Developer Bristol-Myers Squibb; Dana-Farber Cancer Institute; Neon Therapeutics
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Bladder cancer; Glioblastoma; Malignant melanoma; Non-small cell lung cancer

Most Recent Events

  • 11 Nov 2016 Dana-Farber Cancer Institute plans a phase I trial for Renal cell carcinoma (Late-stage disease, Metastatic disease, Combination therapy) in USA (NCT02950766)
  • 01 Oct 2016 Phase-I clinical trials in Bladder cancer (Inoperable/Unresectable, Metastatic disease, Late-stage disease, Second-line therapy or greater, Combination therapy) in USA (Parenteral) (NCT02897765)
  • 01 Oct 2016 Phase-I clinical trials in Malignant melanoma (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Parenteral) (NCT02897765)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top